Eyes on China stocks: Loncar loads new ETF with his picks for most promising biotechs on HKEX and Nasdaq
An investor group based in the Midwest is tapping the booming biotech scene in China to launch a new investment vehicle for traders interested in promising Chinese ventures.
Loncar Investments, founded by independent biotech investor Brad Loncar, selected 28 companies — some listed on the Hong Kong Stock Exchange and the rest on the Nasdaq — to wrap up into an exchange-traded fund: Loncar China BioPharma ETF. The ticker is Nasdaq: $CHNA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.